Fortis Healthcare shares are positioned for potential upside following the company's robust Q4FY26 results, with brokerages maintaining mixed but generally positive views on the hospital stock. According to reports from ET Now, the company reported a 44.23% rise in consolidated profit after tax to ₹271.19 crore for the March 2026 quarter. Revenue from operations demonstrated strong growth of 17.8% year-on-year to ₹2,364.67 crore during the quarter. The strong performance has attracted fresh attention from leading brokerages including Goldman Sachs, Nuvama Institutional Equities, and Motilal Oswal Financial Services, with target prices ranging from ₹950 to ₹1,145, implying upside potential of up to 18%.
Nuvama Institutional Equities maintains a BUY rating with a target price implying around 18% upside potential, as reported by ET Now. The brokerage expects revenue and EBITDA CAGR of 11% and 14% respectively over FY26–28. Goldman Sachs presents a more cautious view, noting that Q4 sales and EBITDA rose 18% and 22% year-on-year respectively, supported by higher occupied beds in the hospitals business. The brokerage highlighted continued improvement in diagnostics profitability but sees a 2% downside risk from current levels. Motilal Oswal Financial Services expects 15% upside potential, citing volume growth, strong occupancy, and Congo momentum as key drivers supporting the Q4 earnings beat.
According to ET Now reports, the positive brokerage outlook is supported by several key factors including volume growth, strong occupancy, and Congo momentum that supported the Q4 earnings beat. The company's brownfield expansion and diagnostics growth are identified as key long-term drivers, despite some trimming of FY27 and FY28 earnings estimates by certain brokerages. The strong operational performance across the hospitals business, supported by higher occupied beds, has contributed to the improved financial metrics and positive market sentiment surrounding the stock.
